Last reviewed · How we verify
The placebo of tong-jiang granules
The placebo of tong-jiang granules is a Small molecule drug developed by Xiyuan Hospital of China Academy of Chinese Medical Sciences. It is currently FDA-approved.
A placebo formulation containing inert ingredients designed to serve as a control comparator in clinical trials of Tong-Jiang granules.
At a glance
| Generic name | The placebo of tong-jiang granules |
|---|---|
| Sponsor | Xiyuan Hospital of China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo, this product contains no active pharmaceutical ingredients and produces no pharmacological effect. It is used in randomized controlled trials to establish the efficacy of the active Tong-Jiang granules formulation by comparison against a non-active control. The placebo allows researchers to distinguish true drug effects from placebo response and natural disease progression.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The placebo of tong-jiang granules CI brief — competitive landscape report
- The placebo of tong-jiang granules updates RSS · CI watch RSS
- Xiyuan Hospital of China Academy of Chinese Medical Sciences portfolio CI